About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

Changchun High & New Technology Industry (Group) Co., Ltd’s unit Changchun Jinsai Pharmaceutical Co., Ltd received a Drug Clinical Trial Approval Notice from the National Medical Products Administration approving a domestically manufactured drug‑regi

2026-10-27

Changchun High & New Technology Industry (Group) Co., Ltd’s unit Changchun Jinsai Pharmaceutical Co., Ltd received a Drug Clinical Trial Approval Notice from the National Medical Products Administration approving a domestically manufactured drug‑registration clinical trial application for injectable GenSci136. GenSci136 is Jinsai’s self‑developed BAFF/APRIL dual‑target antagonist, classified in China as a Class 1 therapeutic biological product and intended for treatment of Sjögren’s syndrome.

Other News
2026-10-27

Market news: The Iranian president has arrived in Moscow, Russia.

Market news: The Iranian president has arrived in Moscow, Russia.
2026-10-27

The A-share advanced packaging sector saw unusual activity, with JCET Group, Tongfu Microelectronics, Huatian Technology, Shenzhen Technology, and Taiji Industry all rising simultaneously. This is reportedly due to news that TSMC plans to raise advan

The A-share advanced packaging sector saw unusual activity, with JCET Group, Tongfu Microelectronics, Huatian Technology, Shenzhen Technology, and Taiji Industry all rising simultaneously. This is reportedly due to news that TSMC plans to raise advanced packaging prices by up to 20%.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.